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Abstract 
Building a Better Phospholamban: Using Structure and Dynamics-Based Design to 
Engineer Therapeutic Mutants for Treating Heart Failure 
Choua Xiong, Adedolapo Ojoawo, Dr. Kim N. Ha 
 
Heart disease is the leading cause of death in the United States. Heart failure, one of 
the chronic conditions of heart disease, is marked by a loss of strength in muscle 
contractility. Impairment in calcium signaling in cardiac muscle cells has a direct impact 
on the development of heart failure. Interactions between an enzyme, the sarcoplasmic 
reticulum Ca2+ ATPase (SERCA), and its regulatory inhibitor, the membrane protein 
phospholamban (PLN), play an important role in the regulation of cardiac muscle 
relaxation and contraction. PLN is a membrane protein that inhibits SERCA, an enzyme 
that facilitates transport of calcium ions into the sarcoplasmic reticulum to allow 
relaxation to occur. Several naturally occurring mutations in PLN lead to inherited heart 
diseases. In order to augment SERCA activity and increase cardiac relaxation, we are 
designing PLN mutants which will be able to selectively increase SERCA activity by 
down-regulating PLN inhibition. The ultimate goal is to identify the most promising PLN 
mutants, deliver them into animal models using gene therapy, and test whether they 
improve cardiac relaxation. Based on the known structure of PLN, we have designed, 
cloned, and isolated new generation of PLN mutants for study and explored the 
interactions between PLN mutants and protein phosphatase 1 (PP1), one of the main 
enzymes that dephosphorylates PLN and controls PLN inhibition activity. We have 
successfully completed preparation of PLN mutant samples for activity assays. These 
interactions will eventually be correlated to changes in SERCA activity to determine if 
the therapeutic mutants can deliver expected results. 
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